RSV-F-PRÄFUSIONSANTIGENE

European patent · EP2707385 · In force

Register entry

Publication number
EP2707385
Application number
EP12722057
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 14, 2012
Published
Mar 19, 2014
Granted
Sep 20, 2017
Protection ends at the latest
May 13, 2032
Next annual fee due
May 31, 2027
IPC classes
C07K 14/135 (2006.01)
Priority
US 201161486005 P 13.05.2011
PCT application
PCT/US2012/037773 14.05.2012
PCT publication
WO2012/158613 22.11.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  4. Jun 1, 2023

    Change

    Published in Swissreg on 01.06.2023

  5. Oct 20, 2017

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 20.10.2017

  6. Sep 20, 2017

    Granted

    Published in Swissreg on 20.09.2017

Parties

Holder

GlaxoSmithKline Biologicals SA

Rue de l'Institut 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

SWANSON, Kurt

Emeryville, CA 94662-8097, US

CARFI, Andrea

Emeryville, CA 94662-8097, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.